• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

载脂蛋白 A-I 模拟肽的结构/功能关系:对高密度脂蛋白抗动脉粥样硬化活性的影响。

Structure/function relationships of apolipoprotein a-I mimetic peptides: implications for antiatherogenic activities of high-density lipoprotein.

机构信息

Baker Heart and Diabetes Institute, PO Box 6492, St Kilda Rd, Melbourne 8008, Australia.

出版信息

Circ Res. 2010 Jul 23;107(2):217-27. doi: 10.1161/CIRCRESAHA.110.216507. Epub 2010 May 27.

DOI:10.1161/CIRCRESAHA.110.216507
PMID:20508181
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2943235/
Abstract

RATIONALE

Apolipoprotein (apoA)-I mimetic peptides are a promising type of anti-atherosclerosis therapy, but how the structural features of these peptides relate to the multiple antiatherogenic functions of HDL is poorly understood.

OBJECTIVE

To establish structure/function relationships of apoA-I mimetic peptides with their antiatherogenic functions.

METHODS AND RESULTS

Twenty-two bihelical apoA-I mimetic peptides were investigated in vitro for the capacity and specificity of cholesterol efflux, inhibition of inflammatory response of monocytes and endothelial cells, and inhibition of low-density lipoprotein (LDL) oxidation. It was found that mean hydrophobicity, charge, size of hydrophobic face, and angle of the link between the helices are the major factors determining the efficiency and specificity of cholesterol efflux. The peptide with optimal parameters was more effective and specific toward cholesterol efflux than human apoA-I. Charge and size of hydrophobic face were also the major factors affecting antiinflammatory properties, and the presence of cysteine and histidine residues was the main factor determining antioxidant properties. There was no significant correlation between capacities of the peptides to support individual functions; each function had its own optimal set of features.

CONCLUSIONS

None of the peptides was equally effective in all the antiatherogenic functions tested, suggesting that different functions of HDL may have different mechanisms and different structural requirements. The results do suggest, however, that rationalizing the design of apoA-I mimetic peptides may improve their therapeutic value and may lead to a better understanding of mechanisms of various antiatherogenic functions of HDL.

摘要

理由

载脂蛋白(apoA)-I 模拟肽是一种很有前途的抗动脉粥样硬化治疗方法,但这些肽的结构特征与高密度脂蛋白(HDL)的多种抗动脉粥样硬化功能之间的关系还知之甚少。

目的

建立载脂蛋白 A-I 模拟肽的结构/功能关系与其抗动脉粥样硬化功能。

方法和结果

在体外研究了 22 种双螺旋载脂蛋白 A-I 模拟肽,以评估其胆固醇外排能力和特异性、抑制单核细胞和内皮细胞炎症反应以及抑制低密度脂蛋白(LDL)氧化的能力。结果发现,平均疏水性、电荷、疏水面大小以及螺旋之间连接的角度是决定胆固醇外排效率和特异性的主要因素。具有最佳参数的肽比人载脂蛋白 A-I 更有效和特异性地进行胆固醇外排。电荷和疏水面大小也是影响抗炎特性的主要因素,而半胱氨酸和组氨酸残基的存在是决定抗氧化特性的主要因素。肽支持各个功能的能力之间没有显著相关性;每种功能都有其最佳的特征集。

结论

在所测试的所有抗动脉粥样硬化功能中,没有一种肽是同样有效的,这表明 HDL 的不同功能可能具有不同的机制和不同的结构要求。然而,结果确实表明,合理化载脂蛋白 A-I 模拟肽的设计可以提高其治疗价值,并可能有助于更好地理解 HDL 的各种抗动脉粥样硬化功能的机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d53f/2943235/193b0907c6f2/nihms-213412-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d53f/2943235/40962f1db094/nihms-213412-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d53f/2943235/4662a6333140/nihms-213412-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d53f/2943235/78d71f496b5a/nihms-213412-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d53f/2943235/526c32a3ca87/nihms-213412-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d53f/2943235/193b0907c6f2/nihms-213412-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d53f/2943235/40962f1db094/nihms-213412-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d53f/2943235/4662a6333140/nihms-213412-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d53f/2943235/78d71f496b5a/nihms-213412-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d53f/2943235/526c32a3ca87/nihms-213412-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d53f/2943235/193b0907c6f2/nihms-213412-f0005.jpg

相似文献

1
Structure/function relationships of apolipoprotein a-I mimetic peptides: implications for antiatherogenic activities of high-density lipoprotein.载脂蛋白 A-I 模拟肽的结构/功能关系:对高密度脂蛋白抗动脉粥样硬化活性的影响。
Circ Res. 2010 Jul 23;107(2):217-27. doi: 10.1161/CIRCRESAHA.110.216507. Epub 2010 May 27.
2
The 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro.5A 载脂蛋白 A-I 模拟肽在体内和体外均具有抗炎和抗氧化作用。
Arterioscler Thromb Vasc Biol. 2010 Feb;30(2):246-52. doi: 10.1161/ATVBAHA.109.200196. Epub 2009 Dec 3.
3
5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice.5A 载脂蛋白模拟肽促进胆固醇流出,减少小鼠动脉粥样硬化。
J Pharmacol Exp Ther. 2010 Aug;334(2):634-41. doi: 10.1124/jpet.110.167890. Epub 2010 May 19.
4
Structure-function relationships in reconstituted HDL: Focus on antioxidative activity and cholesterol efflux capacity.富含高密度脂蛋白的结构与功能关系:重点关注抗氧化活性和胆固醇外排能力。
Biochim Biophys Acta Mol Cell Biol Lipids. 2017 Sep;1862(9):890-900. doi: 10.1016/j.bbalip.2017.05.010. Epub 2017 May 18.
5
High-density lipoprotein reduces the human monocyte inflammatory response.高密度脂蛋白可降低人类单核细胞的炎症反应。
Arterioscler Thromb Vasc Biol. 2008 Nov;28(11):2071-7. doi: 10.1161/ATVBAHA.108.168690. Epub 2008 Jul 10.
6
Apolipoprotein A-I but not high-density lipoproteins are internalised by RAW macrophages: roles of ATP-binding cassette transporter A1 and scavenger receptor BI.载脂蛋白A-I而非高密度脂蛋白被RAW巨噬细胞内化:ATP结合盒转运蛋白A1和清道夫受体BI的作用。
J Mol Med (Berl). 2008 Feb;86(2):171-83. doi: 10.1007/s00109-007-0267-1. Epub 2007 Oct 1.
7
Tyrosine 192 in apolipoprotein A-I is the major site of nitration and chlorination by myeloperoxidase, but only chlorination markedly impairs ABCA1-dependent cholesterol transport.载脂蛋白A-I中的酪氨酸192是髓过氧化物酶进行硝化和氯化的主要位点,但只有氯化会显著损害ABCA1依赖性胆固醇转运。
J Biol Chem. 2005 Feb 18;280(7):5983-93. doi: 10.1074/jbc.M411484200. Epub 2004 Nov 30.
8
Trimerized apolipoprotein A-I (TripA) forms lipoproteins, activates lecithin: cholesterol acyltransferase, elicits lipid efflux, and is transported through aortic endothelial cells.三聚体载脂蛋白A-I(TripA)形成脂蛋白,激活卵磷脂:胆固醇酰基转移酶,引发脂质流出,并通过主动脉内皮细胞运输。
Biochim Biophys Acta. 2011 Dec;1811(12):1115-23. doi: 10.1016/j.bbalip.2011.09.001. Epub 2011 Sep 10.
9
Apolipoprotein A-I Mimetic Peptides: Discordance Between In Vitro and In Vivo Properties-Brief Report.载脂蛋白A-I模拟肽:体外与体内特性的不一致——简要报告
Arterioscler Thromb Vasc Biol. 2017 Jul;37(7):1301-1306. doi: 10.1161/ATVBAHA.117.309523. Epub 2017 May 18.
10
D-4F, an apolipoprotein A-I mimetic peptide, promotes cholesterol efflux from macrophages via ATP-binding cassette transporter A1.D-4F,一种载脂蛋白 A-I 模拟肽,通过三磷酸腺苷结合盒转运体 A1 促进巨噬细胞胆固醇外流。
Tohoku J Exp Med. 2010 Mar;220(3):223-8. doi: 10.1620/tjem.220.223.

引用本文的文献

1
Apolipoprotein A (ApoA) in Neurological Disorders: Connections and Insights.载脂蛋白A(ApoA)在神经系统疾病中的关联与见解
Int J Mol Sci. 2025 Aug 16;26(16):7908. doi: 10.3390/ijms26167908.
2
Synthetic Amphipathic Helical Peptide L-37pA Ameliorates the Development of Acute Respiratory Distress Syndrome (ARDS) and ARDS-Induced Pulmonary Fibrosis in Mice.合成两亲性螺旋肽 L-37pA 可改善急性呼吸窘迫综合征(ARDS)和 ARDS 诱导的小鼠肺纤维化的发展。
Int J Mol Sci. 2024 Aug 1;25(15):8384. doi: 10.3390/ijms25158384.
3
Anti-inflammatory mechanism of Apolipoprotein A-I.

本文引用的文献

1
A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice.一种新型的高密度脂蛋白模拟肽,能高效刺激细胞胆固醇外流,极大地减少了小鼠的动脉粥样硬化。
J Lipid Res. 2010 Jun;51(6):1496-503. doi: 10.1194/jlr.M003665. Epub 2010 Jan 14.
2
The 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro.5A 载脂蛋白 A-I 模拟肽在体内和体外均具有抗炎和抗氧化作用。
Arterioscler Thromb Vasc Biol. 2010 Feb;30(2):246-52. doi: 10.1161/ATVBAHA.109.200196. Epub 2009 Dec 3.
3
An apoA-I mimetic peptide containing a proline residue has greater in vivo HDL binding and anti-inflammatory ability than the 4F peptide.
载脂蛋白 A-I 的抗炎机制。
Front Immunol. 2024 Jul 8;15:1417270. doi: 10.3389/fimmu.2024.1417270. eCollection 2024.
4
High-Density Lipoprotein in Metabolic Disorders and Beyond: An Exciting New World Full of Challenges and Opportunities.代谢紊乱及其他领域中的高密度脂蛋白:一个充满挑战与机遇的全新激动人心的世界。
Pharmaceuticals (Basel). 2023 Jun 8;16(6):855. doi: 10.3390/ph16060855.
5
Inhibition of Vascular Inflammation by Apolipoprotein A-IV.载脂蛋白A-IV对血管炎症的抑制作用。
Front Cardiovasc Med. 2022 Jun 30;9:901408. doi: 10.3389/fcvm.2022.901408. eCollection 2022.
6
Apolipoprotein Mimetic Peptide Inhibits Neutrophil-Driven Inflammatory Damage via Membrane Remodeling and Suppression of Cell Lysis.载脂蛋白模拟肽通过细胞膜重塑和抑制细胞裂解抑制中性粒细胞驱动的炎症损伤。
ACS Nano. 2021 Oct 26;15(10):15930-15939. doi: 10.1021/acsnano.1c03978. Epub 2021 Sep 29.
7
Apolipoprotein and LRP1-Based Peptides as New Therapeutic Tools in Atherosclerosis.载脂蛋白和基于低密度脂蛋白受体相关蛋白1的肽作为动脉粥样硬化新的治疗工具
J Clin Med. 2021 Aug 13;10(16):3571. doi: 10.3390/jcm10163571.
8
HDL and type 2 diabetes: the chicken or the egg?高密度脂蛋白与2型糖尿病:先有鸡还是先有蛋?
Diabetologia. 2021 Sep;64(9):1917-1926. doi: 10.1007/s00125-021-05509-0. Epub 2021 Jul 13.
9
A novel apoA-I mimetic peptide suppresses atherosclerosis by promoting physiological HDL function in apoE mice.一种新型载脂蛋白A-I模拟肽通过促进载脂蛋白E基因敲除小鼠体内生理性高密度脂蛋白功能来抑制动脉粥样硬化。
Br J Pharmacol. 2020 Oct;177(20):4627-4644. doi: 10.1111/bph.15213. Epub 2020 Sep 9.
10
Incorporation of α-methylated amino acids into Apolipoprotein A-I mimetic peptides improves their helicity and cholesterol efflux potential.将α-甲基化氨基酸掺入载脂蛋白 A-I 模拟肽中可提高其螺旋度和胆固醇外排潜力。
Biochem Biophys Res Commun. 2020 May 28;526(2):349-354. doi: 10.1016/j.bbrc.2020.03.070. Epub 2020 Mar 26.
含有脯氨酸残基的载脂蛋白 A-I 模拟肽比 4F 肽具有更强的体内 HDL 结合能力和抗炎能力。
J Lipid Res. 2009 Sep;50(9):1889-900. doi: 10.1194/jlr.M900151-JLR200. Epub 2009 May 11.
4
Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes.重组高密度脂蛋白可增强2型糖尿病患者血浆高密度脂蛋白的抗炎特性和胆固醇流出能力。
J Am Coll Cardiol. 2009 Mar 17;53(11):962-71. doi: 10.1016/j.jacc.2008.12.008.
5
A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all L-amino acids.一种由全L-氨基酸合成的载脂蛋白模拟肽口服递送的新方法。
J Lipid Res. 2009 Aug;50(8):1538-47. doi: 10.1194/jlr.M800539-JLR200. Epub 2009 Feb 18.
6
HDL-replacement therapy: mechanism of action, types of agents and potential clinical indications.高密度脂蛋白替代疗法:作用机制、药物类型及潜在临床适应症。
Expert Rev Cardiovasc Ther. 2008 Oct;6(9):1203-15. doi: 10.1586/14779072.6.9.1203.
7
Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque.输注重组高密度脂蛋白会导致人类动脉粥样硬化斑块发生急性变化。
Circ Res. 2008 Nov 7;103(10):1084-91. doi: 10.1161/CIRCRESAHA.108.182063. Epub 2008 Oct 2.
8
Asymmetry in the lipid affinity of bihelical amphipathic peptides. A structural determinant for the specificity of ABCA1-dependent cholesterol efflux by peptides.双螺旋两亲性肽脂质亲和力的不对称性。肽依赖ABCA1的胆固醇流出特异性的结构决定因素。
J Biol Chem. 2008 Nov 21;283(47):32273-82. doi: 10.1074/jbc.M804461200. Epub 2008 Sep 19.
9
High-density lipoprotein reduces the human monocyte inflammatory response.高密度脂蛋白可降低人类单核细胞的炎症反应。
Arterioscler Thromb Vasc Biol. 2008 Nov;28(11):2071-7. doi: 10.1161/ATVBAHA.108.168690. Epub 2008 Jul 10.
10
Antiatherogenic functionality of high density lipoprotein: how much versus how good.高密度脂蛋白的抗动脉粥样硬化功能:量与质的比较
J Atheroscler Thromb. 2008 Apr;15(2):52-62. doi: 10.5551/jat.e571. Epub 2008 Apr 3.